New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements in Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
The Woodlands, Texas, March 12, 2024 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post hoc analysis of clinical data from its inTandem3 Phase 3 trial demonstrated that treatment with sotagliflozin resulted in improved glycemic control in patients with type 1 diabetes and chronic kidney disease (CKD). In this important patient population, treatment with sotagliflozin successfully lowered A1C, body weight, and systolic blood pressure with safety similar to the total study cohort.
The efficacy and safety data were presented last week at ATTD 2024 - 17th International Conference on Advanced Technologies and Treatments for Diabetes in Florence, Italy.
Using data from the 24-week, multinational, placebo-controlled trial, the effects of sotagliflozin 400 mg daily added to insulin therapy on A1C, body weight, systolic blood pressure, eGFR, total insulin dose, adjudicated severe hypoglycemia and DKA were evaluated in a subgroup of patients (228 [16.3%] of 1402]) with type 1 diabetes and CKD (eGFR <60 mL/min/1.73 m2 and/or UACR ≥30 mg/g).
Relative to placebo, treatment with sotagliflozin led to similar reductions in A1C, body weight and systolic blood pressure in the CKD and total cohorts. Sotagliflozin was associated with similar risks of severe hypoglycemia between the two cohorts.
“Our research team concluded that in patients with type 1 diabetes and CKD, treatment with sotagliflozin had similar A1C, body weight and systolic blood pressure lowering effects as compared to its effect on the total cohort” said David Z.I. Cherney, M.D., Ph. D., Professor in the Department of Medicine at the University of Toronto, and a contributing author of the abstract presented March 7, 2024, at ATTD.
“This research adds important data to the body of evidence supporting our plans to resubmit our New Drug Application for sotagliflozin as an adjunct to insulin therapy in people with type 1 diabetes and CKD,” said Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer. “We are optimistic that sotagliflozin may become an important new tre atment option for this important population.”
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat diseases safely and effectively. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in heart failure, neuropathic pain, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to the therapeutic and commercial potential, research and clinical development and regulatory status of sotagliflozin in type 1 diabetes. In addition, this press release may also contain forward looking statements relating to Lexicon’s financial position and long-term outlook on its business, growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize INPEFA® (sotagliflozin) in heart failure on the timeline and/or at the prices currently contemplated or at all, conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin in type 1 diabetes and other indications, LX9211 and its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2022 and other subsequent disclosure documents filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Lexicon Pharmaceuticals, Inc.
Posted: March 2024
Related articles
- Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission - July 16, 2024
- Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes - June 21, 2024
- Lexicon Voluntarily Withdraws Sotagliflozin New Drug Application and Plans Prompt Resubmission Targeted Early Q2 2022 - February 28, 2022
- FDA Issues Complete Response Letter for Zynquista (sotagliflozin) - March 25, 2019
- FDA Advisory Committee Votes on Zynquista (sotagliflozin) as Treatment for Adults with Type 1 Diabetes - January 17, 2019
- FDA to Review Zynquista (sotagliflozin) as Potential Treatment for Type 1 Diabetes - May 22, 2018
- Lexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults with Type 1 Diabetes - March 26, 2018
Zynquista (sotagliflozin) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.